Monday, November 20, 2017 10:13:08 AM
CRMD - .5066
CorMedix Inc. Announces Common Stock Purchase by Company Directors and Executive Management Team
BERKELEY HEIGHTS, NJ / ACCESSWIRE / November 20, 2017 / CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced a common stock transaction of 624,246 shares at a per share purchase price of $0.48 to members of the Company's Board of Directors, the executive management team and certain employees, as previously announced in association with the recent preferred stock and backstop financing from a long term institutional investor. Gross proceeds from the offering are expected to be approximately $300,000, which will apply against the Backstop Agreement and reduce the total warrants issuable to the investor by 6%.
CorMedix Inc. Announces Common Stock Purchase by Company Directors and Executive Management Team
BERKELEY HEIGHTS, NJ / ACCESSWIRE / November 20, 2017 / CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced a common stock transaction of 624,246 shares at a per share purchase price of $0.48 to members of the Company's Board of Directors, the executive management team and certain employees, as previously announced in association with the recent preferred stock and backstop financing from a long term institutional investor. Gross proceeds from the offering are expected to be approximately $300,000, which will apply against the Backstop Agreement and reduce the total warrants issuable to the investor by 6%.
Join the InvestorsHub Community
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
